Head-To-Head Comparison: Evaxion Biotech A/S (NASDAQ:EVAX) vs. Valneva (NASDAQ:VALN)

Evaxion Biotech A/S (NASDAQ:EVAXGet Rating) and Valneva (NASDAQ:VALNGet Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.

Insider & Institutional Ownership

4.7% of Evaxion Biotech A/S shares are owned by institutional investors. Comparatively, 0.2% of Valneva shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Evaxion Biotech A/S and Valneva’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evaxion Biotech A/S N/A -107.83% -78.88%
Valneva N/A N/A N/A

Analyst Ratings

This is a summary of current ratings and target prices for Evaxion Biotech A/S and Valneva, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evaxion Biotech A/S 0 0 2 0 3.00
Valneva 1 1 4 0 2.50

Evaxion Biotech A/S presently has a consensus target price of $22.00, suggesting a potential upside of 1,082.80%. Valneva has a consensus target price of $36.00, suggesting a potential upside of 46.94%. Given Evaxion Biotech A/S’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Evaxion Biotech A/S is more favorable than Valneva.

Valuation and Earnings

This table compares Evaxion Biotech A/S and Valneva’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Evaxion Biotech A/S N/A N/A -$24.53 million ($1.27) -1.46
Valneva $411.85 million 3.19 -$86.87 million N/A N/A

Evaxion Biotech A/S has higher earnings, but lower revenue than Valneva.

Evaxion Biotech A/S Company Profile (Get Rating)

Evaxion Biotech A/S, an artificial intelligence (AI)-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. Its proprietary AI platforms include PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. The company develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase 1/2a trial for indications, such as metastatic and unresectable melanoma; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in Phase 2b trial for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are in pre-clinical stage for the treatment of infectious diseases. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate; and a clinical trial collaboration and supply agreement with MSD International GmbH and MSD International Business GmbH. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Valneva Company Profile (Get Rating)

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

Receive News & Ratings for Evaxion Biotech A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion Biotech A/S and related companies with MarketBeat.com's FREE daily email newsletter.